tbuckley/cabot-search huggingface dataset:
Hello, goodbye
Authors: Andrew R. Marks
Journal: Journal of Clinical Investigation (2007)

Much has changed in the 5 years since the responsibility for editing the JCI was transferred to Columbia University. Wars and a hurricane have conspired with other factors to overwhelm the national treasury. Support for investigator-initiated research at the NIH is now at a level that jeopardizes the nation’s ability to adequately train future scientists to maintain the country’s leadership in biomedical research. Indeed, there is insufficient support for even the best and brightest biomedical scientists to pursue the frontiers of the sciences at a time of unprecedented opportunities. Human embryonic stem cell research is still being suppressed in the United States. Economic models that enable academic health centers to flourish in the face of increasing challenges and the rising costs of health care have for the most part remained elusive. Translational research has become the buzzword, but there is widespread confusion and disagreement about how to do it. Despite all of these and other challenges to the biomedical research enterprise, the JCI remains vibrant, with record numbers of submissions and a loyal and enthusiastic readership.
Closed Relation Between Carotid and Ascending Aortic Atherosclerosis in Cardiac Patients
Authors: Ioannis E. Kallikazaros, Costas P. Tsioufis, Christodoulos I. Stefanadis, Christos E. Pitsavos, Pavlos K. Toutouzas
Journal: Circulation (2000)

Background —Carotid atherosclerosis and aortic atherosclerosis are both associated with coronary artery disease and cerebral thromboembolism. However, the relationship between asymptomatic carotid and aortic atherosclerosis is not well known. Methods and Results —Sixty-two consecutive cardiac patients (mean age 57 years) without a history of atherosclerotic cardiovascular disease who were referred for transesophageal echocardiography were included. By means of a high-resolution ultrasound technique, normal carotid arteries were found in 12 patients (19.4%), whereas 15 patients (24.2%) had increased intima-media thickness, and the remaining 35 patients (56.5%) had atherosclerotic plaques (intima-media thickness ≥1.3 mm). Transesophageal echocardiography characterized ascending aortic intimal morphology as normal in 1 patient (1.6%), as thickening in 22 patients (35.5%), and as atherosclerotic plaques in 39 patients (62.9%). Patients with both carotid and aortic plaques were older compared with patients without plaques; also, a higher percentage of patients with carotid and aortic plaques suffered from hypertension and diabetes mellitus compared with patients without plaques ( P &lt;0.001). The incidence of carotid plaques was 74.3% (29 of 39 patients) in the subgroup with aortic plaques; there was a stepwise increase in the percentage of patients with carotid plaques among the patients with increasing grades of aortic atherosclerosis. Furthermore, the incidence of ascending aortic plaques was 82.8% (29 of 35 patients) in the subgroup with carotid plaques. Regression analysis revealed that age and carotid plaques were independently related to the presence of aortic plaques. In the entire study population, the presence of carotid plaques had a high positive predictive value (83%), an acceptable sensitivity (75%) and specificity (74%), and a relatively low negative predictive value (63%) for the presence of aortic plaques. Conclusions —In cardiac patients without clinical evidence of atherosclerotic cardiovascular disease, a high prevalence of combined aortic and carotid plaques were detected. The presence of carotid plaque reflects the presence of aortic plaque, whereas the absence of carotid plaque may not reflect the absence of aortic plaque.
Selective parasympathetic innervation of subcutaneous and intra-abdominal fat — functional implications
Authors: Felix Kreier, Eric Fliers, Peter J. Voshol, Corbert G. Van Eden, Louis M. Havekes, Andries Kalsbeek, Caroline L. Van Heijningen, Arja A. Sluiter, Thomas C. Mettenleiter, Johannes A. Romijn, Hans P. Sauerwein, Ruud M. Buijs
Journal: Journal of Clinical Investigation (2002)

The wealth of clinical epidemiological data on the association between intra-abdominal fat accumulation and morbidity sharply contrasts with the paucity of knowledge about the determinants of fat distribution, which cannot be explained merely in terms of humoral factors. If it comes to neuronal control, until now, adipose tissue was reported to be innervated by the sympathetic nervous system only, known for its catabolic effect. We hypothesized the presence of a parasympathetic input stimulating anabolic processes in adipose tissue. Intra-abdominal fat pads in rats were first sympathetically denervated and then injected with the retrograde transneuronal tracer pseudorabies virus (PRV). The resulting labeling of PRV in the vagal motor nuclei of the brain stem reveals that adipose tissue receives vagal input. Next, we assessed the physiological impact of these findings by combining a fat pad–specific vagotomy with a hyperinsulinemic euglycemic clamp and RT-PCR analysis. Insulin-mediated glucose and FFA uptake were reduced by 33% and 36%, respectively, whereas the activity of the catabolic enzyme hormone-sensitive lipase increased by 51%. Moreover, expression of resistin and leptin mRNA decreased, whereas adiponectin mRNA did not change. All these data indicate an anabolic role for the vagal input to adipose tissue. Finally, we demonstrate somatotopy within the central part of the autonomic nervous system, as intra-abdominal and subcutaneous fat pads appeared to be innervated by separate sympathetic and parasympathetic motor neurons. In conclusion, parasympathetic input to adipose tissue clearly modulates its insulin sensitivity and glucose and FFA metabolism in an anabolic way.
The Physical Basis of Emotional Disorder. Correction
Journal: BMJ (1924)

H. McM." asks for a full list of medical articles, contributions, or other medical literature dealing with: (1) the earliest refer- ences to or description of the percussion area known as Kronig's isthmus; (2) the clinical value of the variations from normal in the extent of the area; and (3) any descriptive article on the precautions to be observed in making the defiuition of the area sitrictly accurate.CHLORODYNE.'M." asks why Collis Browne's chilorodyne may be sold over the counter by chemists in 1-oz.bottles without being entered on
THEOBALD SMITH—COMPARATIVE MICROBIOLOGIST
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
THE PATHOLOGY OF MERCURY POISONING
Journal: JAMA (1918)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reply
Authors: Fu‐Ming Chang, Yen‐Po Wang, Ching‐Liang Lu
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. Author names in bold designate shared co‐first authorship. Reply: We really appreciate the opinions from Dr. Lin regarding methodological issues of our recent published article.1 Indeed, our design was arranged to avoid the bias from misclassified immortal time, and we agree that this measurement may lead to a possible selection bias. We also understand that hepatotoxicity may be a concern for prescribing statin to patients with cirrhosis for some physicians, which might lead to further selection bias by enrolling these patients with cirrhosis with better liver reserve in the statin group. In this retrospective study, we tried our best using the following strategies to minimize the impact of this potential selection bias. First of all, those with a history of any hepatic decompensations or hepatocellular carcinoma 180 days before or after the index date in either groups were excluded from the analysis. Then, we used a propensity‐score–matched design by including 14 covariates to minimize the bias from confounding variables. And the Charlson comorbidity index score did show comparability in both stain and control groups. Finally, the follow‐up duration was also matched between the two groups. With these measurements, we believed that the two groups were balanced at baseline characteristics and in follow‐up period. Then, the impact from selection bias can be minimized. Actually, besides the two studies (including the current one) showing beneficial effects of statin in reducing decompensation rate among hepatitis B– and hepatitis C–related cirrhosis,1 a recent population study also revealed similar beneficial effects of statin in patients with alcoholic cirrhosis.3 Furthermore, a recent prospective study showed that adding simvastatin to standard therapy was associated with a survival benefit for patients with Child‐Pugh class A or B cirrhosis.4 Nevertheless, we agreed that there may exist unmeasured confounders that would impact on our results. Future prospective studies are necessary to clarify whether statin can be beneficial in patients with cirrhosis in decreasing the decompensation incidence. Regarding the interval between the date of diagnosis of cirrhosis and date of first statin prescription, we are able to provide such data. However, we do not believe such data would have any significant impact on our measured outcomes.
Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: Clinical outcome according to risk score.
Authors: Manuela Schmidinger, Camillo Porta, Stephane Oudard, Gwénaël Dénéchère, Yves Brault, Lucile Serfass, Nuno Matos Costa, James M. G. Larkin
Journal: Journal of Clinical Oncology (2019)

606 Background: ADONIS, an ongoing, observational study in 9 EU countries, evaluates treatment patterns/outcomes in patients (pts) with metastatic renal cell carcinoma treated with 1st-line (1L) sunitinib (SU) and/or 2nd-line (2L) axitinib (AX) post SU. Analysis of the data is planned in 4 parts, to occur stepwise as data matures; evaluation of SU efficacy in intermediate (INT) risk pts is presented here. Future analyses include sequencing data, SU followed by AX and other treatments (cabozantinib, nivolumab and others); SU and AX therapy management strategies, and quality of life. Methods: Pts enroll at start of 1L SU or 2L AX post SU. Data cutoff: May 31, 2018. Analysis focused on 1L SU. Results: 467 pts, median age 64 y (range 31–90), 77.7% were male, with ECOG PS &lt; 2 = 90.2% and ECOG PS ≥ 2 = 9.8% at SU initiation. Overall median progression-free survival (mPFS) was 10.4 mo (95% CI 9.3–12.5), and median overall survival (mOS) 34.0 mo (95% CI 28.3–46.6). Data on individual risk factors (RF) were available for 120 pts, allowing analysis by INT 1RF and INT 2RF groups for this subset. Clinical trial information: NCT02184416. Conclusions: For pts overall and by risk group stratification, survival estimates were aligned with improvements in clinical practice over the past decade. In pts with INT risk with 1RF, OS was very similar to pts with good risk. However further exploration is needed to confirm these observations.[Table: see text]
La cholécystectomie sans drainage (cholécystectomie idéale)
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Timelessness
Authors: T. S. Danowski
Journal: JAMA (1966)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Lectures on the Treatment of Fibroid Tumors of the Uterus.
Journal: JAMA (1897)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Outcomes and safety of sorafenib in elderly patients with advanced hepatocellular carcinoma (HCC).
Authors: Dimitrios Ziogas, Kiruthikah Thillai, Ippokratis Korantzis, MH Ruhe Chowdhury, Dionysios Papadatos-Pastos, Abid Suddle, John O'Grady, Nigel Heaton, Paul J. Ross, Debashis Sarker
Journal: Journal of Clinical Oncology (2015)

435 Background: HCC is the third commonest malignancy worldwide, with the highest incidence rates in patients over 75 years of age. Although sorafenib is used for patients with advanced HCC, there are concerns about the outcomes and tolerability in this age group. Methods: We conducted a retrospective study of 190 patients treated with sorafenib (177 with sorafenib alone, 17 patients with a combination of sorafenib and erlotinib/placebo within the SEARCH trial). Patient demographics and outcomes were recorded. Results: 190 patients were identified with a median age of 66 (26-87). 151 patients were &lt;75 years old (yrs) and 39 patients were &gt;75. 157 patients were male and 33 female. Underlying liver disease in the over 75 group were: non-alcoholic fatty liver disease (N=14, 35.9%), unknown aetiology (N=14, 35.9%), alcoholic liver disease (N=7, 17.9%), hepatitis C (N=2, 5.1%), hepatitis B (N=1, 2.56%,) and autoimmune hepatitis (N=1, 2.56%). 33 patients were Child-Pugh A status when starting sorafenib (A5=25, A6=8) and 6 patients were Child-Pugh B (B7=5, B8=1). There was no statistically significant difference in OS between patients over the age of 75 and younger (7.1m for &gt;75 yrs and 10.4 &lt;75 yrs p=0.360), or in PFS (4.2m vs. 6.8m [p=0.539]). There was also no increase in G3/4 toxicities between both groups of patients with comparable incidences of G3/4 diarrhoea (4.7% &lt;75 vs. 2.6% ≤75 p=0.481), skin toxicity (6.6% vs. 5.1% p=0.537), fatigue (7.3% vs. 7.7% p =0.58) and deteriorating liver function (2.6% vs. 7.3% p = 0.25). There was no difference between the incidence of dose reductions or interruptions (34% vs. 35.9% p=0.5). Conclusions: Our study suggests that patients aged 75 or older appear to tolerate treatment with sorafenib well with comparable toxicities to those less than 75. We also found no significant differences in survival. With an aging population and increasing incidences of HCC, further prospective evidence is needed to identify safety and survival outcomes in this important group of patients.
On the Actions of Picrotoxine, and the Antagonism between Picrotoxine and Chloral Hydrate
Authors: J. C. Browne
Journal: BMJ (1875)

and constitutional symptoms; that is, between local pathological changes and general constitutional disturbance.This evidently becomes necessary for the purposes of treatment.Allowiiag that the local action of septic agents is the production of those changes of tissue which we term inflammation, the question arises whether there are other causes for the same effects as well as septic material.
Incorrect Wording
Authors: Alon Harris, Hanna Garzozi, Hak Chung
Journal: JAMA (1999)

that can achieve reversal of ocular vasospasm as well as improvement of ocular circulation.In the last 30 years many publications have attested that (a) ocular blood flow is compromised by glaucoma; (b) the insult responsible can be vasospastic, and therefore reversible 2 ; and (c) the extent of vasospasm can be correlated with degree of visual defect. 3It is irrelevant whether ischemia is the primary insult or a result of increased pressure, since improvement of circulation by treatment with vasodilators such as calcium channel blockers has been shown to benefit glaucoma patients. 4In addition, reversal of vasospasm using carbon dioxide has also been shown to be effective in a study of low-tension glaucoma patients. 5We therefore believe that in the future, the most effective glaucoma drug will not only reduce intraocular pressure and inhibit the cascade of events leading to apoptosis but also will ensure adequate circulation in the optic nerve head and reverse ischemia and vasospasm in those locations.
Tuberculosis
Authors: Donald S. King
Journal: New England Journal of Medicine (1952)

SO MANY articles have been written about tuberculosis in the past two years, and the subject is so complex, that it was decided to present this review from the standpoint not of the tuberculosis specialist but from that of the workers in other branches of medicine who might be interested in keeping abreast of the recent progress in this now particularly fascinating field. For this reason the main article is largely a statement of my own conclusions, and the comparatively short bibliography lists only articles in the standard, easily available journals.The present attitude on the treatment of tuberculosis is . . .
From the Health Care Financing Administration
Authors: L. B. Hays
Journal: JAMA (1989)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
GPI-anchored receptor clusters transiently recruit Lyn and Gα for temporary cluster immobilization and Lyn activation: single-molecule tracking study 1
Authors: Kenichi G.N. Suzuki, Takahiro K. Fujiwara, Fumiyuki Sanematsu, Ryota Iino, Michael Edidin, Akihiro Kusumi
Journal: The Journal of Experimental Medicine (2007)
EPF的lncRNA多态性
Authors: S.C. Lobo‐Alves, D.G. Augusto, W.C.S. Magalhães, E. Tarazona‐Santos, M.F. Lima‐Costa, M.L. Barreto, B.L. Horta, R.C. Almeida, M.L. Petzl‐Erler
Journal: British Journal of Dermatology (2019)